Literature DB >> 1318048

Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine.

N Cammack1, P Rouse, C L Marr, P J Reid, R E Boehme, J A Coates, C R Penn, J M Cameron.   

Abstract

The metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine (3TC) was examined in human immunodeficiency virus type 1 (HIV-1)-infected and mock-infected human cells. 3TC 5'-triphosphate levels accumulated comparably in HIV-1-infected and mock-infected phytohaemagglutinin-stimulated peripheral blood lymphocytes (PBL) and reached 40% or more of total intracellular 3TC metabolites after 4 hr. The rate of decay of 3TC triphosphate in HIV-1-infected and mock-infected PBL measured as a half-life (T1/2) ranged from 10.5 to 15.5 hr. 3TC did not significantly affect metabolism of deoxynucleotides in the U937 cell line, and was shown to be resistant to the action of human platelet pyrimidine nucleoside phosphorylase.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318048     DOI: 10.1016/0006-2952(92)90162-c

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  32 in total

1.  Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.

Authors:  W E Delaney; T G Miller; H C Isom
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Interferon-alpha response in chronic hepatitis B-transfected HepG2.2.15 cells is partially restored by lamivudine treatment.

Authors:  Shi-He Guan; Mengji Lu; Petra Grünewald; Michael Roggendorf; Guido Gerken; Jörg F Schlaak
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

3.  Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.

Authors:  Stephen Kewn; Patrick G Hoggard; Sean D Sales; Kevin Jones; Bridget Maher; Saye H Khoo; David J Back
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents.

Authors:  Zexun Zhou; John H Rodman; Patricia M Flynn; Brian L Robbins; Carrie K Wilcox; David Z D'Argenio
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 5.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 6.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

Review 7.  Clinical pharmacokinetics of lamivudine.

Authors:  M A Johnson; K H Moore; G J Yuen; A Bye; G E Pakes
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

8.  Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV.

Authors:  R Bruno; M B Regazzi; V Ciappina; P Villani; P Sacchi; M Montagna; R Panebianco; G Filice
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  Exonuclease removal of dideoxycytidine (zalcitabine) by the human mitochondrial DNA polymerase.

Authors:  Jeremiah W Hanes; Kenneth A Johnson
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

10.  Pharmacodynamics of (-)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans.

Authors:  S J Hurwitz; B C Tennant; B E Korba; J L Gerin; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.